Mounjaro vs Trulicity
Side-by-side cost comparison based on Medicare Part D data
Mounjaro
Tirzepatide
Manufactured by Eli Lilly
Trulicity
Dulaglutide
Manufactured by Eli Lilly
Trulicity costs 30% less per claim than Mounjaro ($473.00 vs $673.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Mounjaro | Trulicity |
|---|---|---|
| Avg Cost Per Claim | $673.00 | $473.00 |
| Total Medicare Spending | $2.5B | $4.2B |
| Total Beneficiaries | 524,000 | 985,000 |
| Total Claims | 3,680,000 | 8,920,000 |
| Annual Cost/Patient | $4,729.00 | $4,279.00 |
| Year-over-Year Change | +312.4% | -4.8% |
| Generic Available | No | No |
| Patent Expiration | May 13, 2036 | Sep 18, 2027 |
| Manufacturer | Eli Lilly | Eli Lilly |
| Condition | Diabetes | Diabetes |
| Generic Name | Tirzepatide | Dulaglutide |
Mounjaro vs Trulicity: What the Data Shows
Mounjaro (Tirzepatide) and Trulicity (Dulaglutide) are both used to treat diabetes. Based on Medicare Part D data, Trulicity costs $473.00 per claim, which is 30% less than Mounjaro at $673.00 per claim.
Medicare spent $2.5B on Mounjaro and $4.2B on Trulicity. In terms of patient reach, Trulicity serves more beneficiaries (985,000 vs 524,000).
Year-over-year spending changed +312.4% for Mounjaro and -4.8% for Trulicity. Mounjaro saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Mounjaro patent expires May 13, 2036. Trulicity patent expires Sep 18, 2027.
Frequently Asked Questions
Trulicity is cheaper at $473.00 per claim, compared to $673.00 for Mounjaro. That makes Trulicity about 30% less expensive per claim based on Medicare Part D data.
Yes, both Mounjaro and Trulicity are used to treat diabetes. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Mounjaro patent expires May 13, 2036. Trulicity patent expires Sep 18, 2027.
Medicare Part D spent $2.5B on Mounjaro covering 524,000 beneficiaries, and $4.2B on Trulicity covering 985,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.